In a heart failure patient who develops cholestasis while on sacubitril‑valsartan (Entresto), what steps should be taken regarding the drug and what alternative heart‑failure regimen is recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Discontinue Sacubitril-Valsartan Immediately and Switch to Standard ACE Inhibitor or ARB-Based Heart Failure Therapy

If a heart failure patient develops cholestasis while on sacubitril-valsartan (Entresto), you must discontinue the drug immediately and transition to an alternative RAAS inhibitor-based regimen, specifically an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB), combined with a beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor as tolerated.

Immediate Management Steps

1. Stop Sacubitril-Valsartan

  • Discontinue immediately upon recognition of cholestasis
  • The FDA label does not specifically list cholestasis as a contraindication, but hepatotoxicity requires immediate cessation 1
  • Document the adverse reaction clearly in the medical record to prevent future re-exposure

2. Assess Severity and Etiology

  • Confirm cholestasis with liver function tests (elevated alkaline phosphatase, GGT, direct bilirubin)
  • Rule out other causes: biliary obstruction, other medications, viral hepatitis, autoimmune conditions
  • Check for signs of hepatic decompensation (coagulopathy, encephalopathy, ascites)
  • If severe hepatotoxicity is present, consider hepatology consultation

3. Washout Period Considerations

  • If switching TO an ACEI: Allow 36 hours washout from last sacubitril-valsartan dose before starting ACEI to minimize angioedema risk 1
  • If switching TO an ARB: No washout period required; can start immediately 2

Alternative Heart Failure Regimen

Foundational Four-Pillar GDMT (Without ARNI)

Pillar 1: RAAS Inhibition

  • First choice: ACE Inhibitor (if no prior intolerance)

    • Start low dose (e.g., enalapril 2.5 mg BID, lisinopril 5 mg daily, ramipril 2.5 mg daily)
    • Titrate every 2 weeks to target doses shown in trials 3, 2
    • Monitor BP, renal function, and potassium closely
  • Alternative: ARB (if ACEI-intolerant due to cough or prior angioedema)

    • Valsartan 40 mg BID or losartan 25 mg daily initially
    • Titrate to target doses (valsartan 160 mg BID, losartan 150 mg daily) 3, 2, 4

Pillar 2: Beta-Blocker

  • Continue or initiate evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol)
  • These are independent of ARNI and should be maintained 3, 4
  • Target heart rate 50-60 bpm if tolerated

Pillar 3: Mineralocorticoid Receptor Antagonist

  • Spironolactone 12.5-25 mg daily or eplerenone 25 mg daily
  • Essential for mortality reduction in HFrEF 3, 4
  • Monitor potassium and creatinine closely, especially when combined with ACEI/ARB
  • Consider potassium binders (patiromer) if hyperkalemia develops rather than stopping MRA 5

Pillar 4: SGLT2 Inhibitor

  • Dapagliflozin 10 mg daily or empagliflozin 10 mg daily
  • Can be started immediately; does not lower BP significantly 6
  • Reduces hyperkalemia risk when combined with RAAS inhibitors 5
  • Provides mortality and hospitalization benefits independent of other therapies

Monitoring Strategy Post-Transition

First 1-2 Weeks:

  • Check BP (supine and standing), heart rate, symptoms
  • Assess volume status; adjust diuretics as needed
  • Monitor for symptomatic hypotension or orthostasis

At 1-2 Weeks:

  • Recheck electrolytes (potassium, sodium), renal function (creatinine, eGFR)
  • Liver function tests to ensure cholestasis is resolving
  • Uptitrate ACEI/ARB if tolerated

Ongoing (Every 2-4 Weeks During Titration):

  • Continue uptitrating ACEI/ARB toward target doses
  • Monitor potassium and creatinine with each dose increase
  • Accept up to 30% increase in creatinine if stable and non-oliguric 2
  • Tolerate potassium up to 5.5 mEq/L with close monitoring 5

Key Clinical Pitfalls to Avoid

Do Not:

  • Re-challenge with sacubitril-valsartan after cholestasis—this represents a serious adverse reaction
  • Combine ACEI + ARB routinely; only consider if BP uncontrolled and with careful monitoring for hyperkalemia and renal dysfunction 3
  • Stop all RAAS inhibition due to mild hyperkalemia or modest creatinine elevation—use strategies to maintain therapy 5
  • Delay SGLT2 inhibitor initiation—it reduces hyperkalemia risk and improves outcomes 5

Do:

  • Prioritize maintaining GDMT even at lower doses rather than complete withdrawal 5, 6
  • Use potassium binders (patiromer) if hyperkalemia limits RAAS inhibitor dosing 5
  • Educate patients about transient dizziness/hypotension being expected with life-prolonging medications 6
  • Consider rechallenge with ACEI/ARB at lower doses if initially not tolerated—many patients tolerate on retry 5

Special Considerations

If Patient Has Low Blood Pressure (<90 mmHg systolic):

  • Start with SGLT2 inhibitor and MRA first (neither significantly lowers BP) 6
  • Add low-dose ACEI/ARB with very gradual uptitration
  • Sometimes cardiac output improves with GDMT, allowing better BP tolerance over time 6

If Patient Has Renal Dysfunction (eGFR <60):

  • Start ACEI/ARB at lowest dose
  • More frequent monitoring of potassium and creatinine
  • Higher risk of adverse events but still beneficial if carefully managed 5, 2
  • SGLT2 inhibitors remain beneficial even with reduced eGFR

If Patient Has Hyperkalemia History:

  • SGLT2 inhibitors reduce hyperkalemia risk—start early 5
  • Consider prophylactic potassium binder (patiromer) to maintain RAAS inhibition 5
  • Dietary potassium restriction counseling
  • Avoid potassium-sparing diuretics beyond MRA

Cost and Formulary Considerations:

  • Generic ACEIs and ARBs are widely available and inexpensive
  • SGLT2 inhibitors may require prior authorization but have strong outcome data
  • MRAs (spironolactone) are generic and affordable

This regimen provides comprehensive, evidence-based heart failure management without sacubitril-valsartan, addressing all four pillars of GDMT for HFrEF while avoiding re-exposure to the medication that caused cholestasis 3, 2, 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.